Under Armour (UAA.US) expects restructuring costs to double, significantly raising its 2025 fiscal year loss guidance.
Under Armour updated its restructuring plan for 2025 on Monday, leading to a significant increase in the loss guidance for the 2025 fiscal year.
Under Armour (UAA.US) updated its restructuring plan for 2025 on Monday, leading to a significant increase in the loss guidance for the 2025 fiscal year. Under Armour expects to incur approximately $140 million to $160 million in pre-tax restructuring and related expenses in the 2025 and 2026 fiscal years; and projects an operating loss of $220 million to $240 million for the 2025 fiscal year, compared to the previous estimate of a loss of $194 million to $214 million. The company's stock price dropped over 4% on Monday.
Previously, the company had anticipated pre-tax restructuring and related expenses of approximately $70 million to $90 million, but after further evaluation, they identified $70 million related to costs in exiting a primary distribution facility in California. Therefore, Under Armour now expects to incur approximately $140 million to $160 million in pre-tax restructuring and related expenses in the 2025 and 2026 fiscal years.
The company updated its outlook for the 2025 fiscal year, projecting an operating loss of $220 million to $240 million, compared to the previous estimate of a loss of $194 million to $214 million. Diluted loss per share is now expected to be $0.58 to $0.61, compared to the previous estimate of $0.53 to $0.56; adjusted diluted earnings per share are projected to be $0.19 to $0.22.
Related Articles

GREAT CHI HLDGS (00021): Wong Man Hei appointed as a new member of the nomination committee

Shandong Sito Bio-technology (300583.SZ): The chemical raw material drug budenide passed the drug GMP compliance inspection.

CH AGRI-PROD EX (00149) releases annual performance, with a net profit attributable to shareholders of 7.8 million Hong Kong dollars, an increase of 5.4% year-on-year.
GREAT CHI HLDGS (00021): Wong Man Hei appointed as a new member of the nomination committee

Shandong Sito Bio-technology (300583.SZ): The chemical raw material drug budenide passed the drug GMP compliance inspection.

CH AGRI-PROD EX (00149) releases annual performance, with a net profit attributable to shareholders of 7.8 million Hong Kong dollars, an increase of 5.4% year-on-year.

RECOMMEND

Trump Signals End to Trade Talks, Vows to Impose Tariffs Unilaterally Ahead of July 9 Deadline
30/06/2025

One License Unlocks HKD 23.4 Billion Surge: Unpacking Hong Kong’s Ambitions as a Global Virtual Asset Hub
30/06/2025

16 Companies Submit IPO Applications in One Day; Hong Kong IPO Fundraising Hits Three-Year High
30/06/2025